AbbVie (ABBV) Short term Debt (2012 - 2026)

AbbVie (ABBV) posted quarterly Short term Debt of $6.1 billion for Q4 2025, up 205.55% quarter-over-quarter from $2.0 billion in Q3 2025.

AbbVie (ABBV) Short term Debt (2012 - 2026) Analysis & Trends

AbbVie (ABBV) has reported Short term Debt for 14 consecutive years, with $6.1 billion the latest figure, recorded in Q4 2025.

In Q4 2025, Short term Debt changed N/A year-over-year to $6.1 billion; the TTM figure through Dec 2025 stood at $6.1 billion (changed N/A YoY), while the FY2025 annual figure was $6.1 billion, changed N/A from the prior year.
Short term Debt rose to $6.1 billion in Q4 2025 per ABBV's latest filing, from $2.0 billion in the prior quarter.
Across five years, Short term Debt topped out at $12.6 billion in Q2 2024 and bottomed at $14.0 million in Q4 2021.
Historically, Short term Debt has averaged $5.9 billion across 5 years, with a median of $5.6 billion in 2023.
Annual changes were most pronounced in 2021 — Short term Debt plunged 99.83% — and 2022, when it surged 57381.25%.
AbbVie's Short term Debt stood at $14.0 million in 2021, then jumped by 29435.71% to $4.1 billion in 2022, then surged by 73.91% to $7.2 billion in 2023, then jumped by 74.8% to $12.6 billion in 2024, then tumbled by 51.82% to $6.1 billion in 2025.
Business Quant data shows ABBV's Short term Debt at $6.1 billion in Q4 2025, $2.0 billion in Q3 2025, and $2.0 billion in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	648.02 Bn	627.27 Bn	17.26 Bn
2	AbbVie	467.00 Bn	460.43 Bn	12.70 Bn
3	Merck	373.58 Bn	366.43 Bn	12.21 Bn
4	Novartis Ag	299.43 Bn	291.74 Bn	11.24 Bn
5	Astrazeneca	256.09 Bn	251.19 Bn	12.86 Bn
6	Amgen	235.35 Bn	221.36 Bn	7.24 Bn
7	Gilead Sciences	179.91 Bn	176.73 Bn	6.22 Bn
8	Pfizer	159.32 Bn	147.62 Bn	10.94 Bn
9	Gsk	104.91 Bn	100.74 Bn	8.24 Bn
10	Sanofi	54.69 Bn	47.31 Bn	10.79 Bn

Download Data